Selected article for: "SDMA symmetric dimethylarginine and symmetric dimethylarginine"

Author: Yu, Jane; Kimble, Benjamin; Norris, Jacqueline M.; Govendir, Merran
Title: Pharmacokinetic Profile of Oral Administration of Mefloquine to Clinically Normal Cats: A Preliminary In-Vivo Study of a Potential Treatment for Feline Infectious Peritonitis (FIP)
  • Cord-id: afzpxxjp
  • Document date: 2020_6_8
  • ID: afzpxxjp
    Snippet: SIMPLE SUMMARY: In searching for antiviral agents against feline coronaviruses and feline caliciviruses, mefloquine, a human anti-malarial drug, has been demonstrated to reduce viral load of feline coronaviruses and feline calicivirus in infected cells. In this study, mefloquine was administered orally to seven clinically healthy cats twice weekly for four doses and mefloquine concentrations in blood were measured to investigate the pharmacokinetic profile—the movement of drug in the body. The
    Document: SIMPLE SUMMARY: In searching for antiviral agents against feline coronaviruses and feline caliciviruses, mefloquine, a human anti-malarial drug, has been demonstrated to reduce viral load of feline coronaviruses and feline calicivirus in infected cells. In this study, mefloquine was administered orally to seven clinically healthy cats twice weekly for four doses and mefloquine concentrations in blood were measured to investigate the pharmacokinetic profile—the movement of drug in the body. The maximum blood concentration of mefloquine was 2.71 ug/mL and was reached 15 h after a single oral dose was administered. Mefloquine side effects included vomiting following administration without food in some cats, and mild increases in symmetric dimethylarginine (SDMA), an early kidney biomarker. This study provides valuable information on mefloquine’s profile in cats as an introductory step towards investigating it as a potential treatment for feline coronavirus and feline calicivirus infection in cats. ABSTRACT: The pharmacokinetic profile of mefloquine was investigated as a preliminary study towards a potential treatment for feline coronavirus infections (such as feline infectious peritonitis) or feline calicivirus infections. Mefloquine was administered at 62.5 mg orally to seven clinically healthy cats twice weekly for four doses and mefloquine plasma concentrations over 336 h were measured using high pressure liquid chromatography (HPLC). The peak plasma concentration (Cmax) after a single oral dose of mefloquine was 2.71 ug/mL and time to reach Cmax (Tmax) was 15 h. The elimination half-life was 224 h. The plasma concentration reached a higher level at 4.06 ug/mL when mefloquine was administered with food. Adverse effects of dosing included vomiting following administration without food in some cats. Mild increases in serum symmetric dimethylarginine (SDMA), but not creatinine, concentrations were observed. Mefloquine may provide a safe effective treatment for feline coronavirus and feline calicivirus infections in cats.

    Search related documents:
    Co phrase search for related documents
    • acid glycoprotein and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acid glycoprotein and acute phase protein: 1, 2, 3, 4, 5, 6, 7, 8
    • acid glycoprotein and liver dysfunction: 1
    • acute kidney injury and liver dysfunction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute kidney injury and liver enzyme: 1, 2, 3
    • acute kidney injury and liver function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute phase and liver dysfunction: 1, 2, 3, 4
    • acute phase and liver enzyme: 1, 2
    • acute phase and liver function: 1, 2, 3, 4, 5, 6, 7
    • acute phase protein and liver enzyme: 1